139 related articles for article (PubMed ID: 36159851)
1. LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.
Corrales L; Hipp S; Martin K; Sabarth N; Tirapu I; Fuchs K; Thaler B; Walterskirchen C; Bauer K; Fabits M; Bergmann M; Binder C; Chetta PM; Vogt AB; Adam PJ
Front Immunol; 2022; 13():1008764. PubMed ID: 36159851
[TBL] [Abstract][Full Text] [Related]
2. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
Giordano G; Parcesepe P; D'Andrea MR; Coppola L; Di Raimo T; Remo A; Manfrin E; Fiorini C; Scarpa A; Amoreo CA; Conciatori F; Milella M; Caruso FP; Cerulo L; Porras A; Pancione M
J Exp Clin Cancer Res; 2019 Jan; 38(1):28. PubMed ID: 30670049
[TBL] [Abstract][Full Text] [Related]
3. Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer.
Wang P; Sun LL; Clark R; Hristopoulos M; Chiu CPC; Dillon M; Lin W; Lo AA; Chalsani S; Das Thakur M; Zimmerman Savill KM; Rougé L; Lupardus P; Piskol R; Husain B; Ellerman D; Shivva V; Leong SR; Ovacik M; Totpal K; Wu Y; Spiess C; Lee G; Leipold DD; Polson AG
Mol Cancer Ther; 2022 Jun; 21(6):974-985. PubMed ID: 35364611
[TBL] [Abstract][Full Text] [Related]
4. MHC class III lymphocyte antigens 6 as endogenous immunotoxins: Unlocking immunotherapy in proficient mismatch repair colorectal cancer.
Giordano G; Pancione M
WIREs Mech Dis; 2024; 16(1):e1631. PubMed ID: 37818781
[TBL] [Abstract][Full Text] [Related]
5. Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo.
Passariello M; Yoshioka A; Takahashi K; Hashimoto SI; Inoue T; Nakamura K; De Lorenzo C
J Exp Clin Cancer Res; 2022 Sep; 41(1):269. PubMed ID: 36071464
[TBL] [Abstract][Full Text] [Related]
6. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
7. Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer.
Tapia-Galisteo A; Sánchez Rodríguez Í; Aguilar-Sopeña O; Harwood SL; Narbona J; Ferreras Gutierrez M; Navarro R; Martín-García L; Corbacho C; Compte M; Lacadena J; Blanco FJ; Chames P; Roda-Navarro P; Álvarez-Vallina L; Sanz L
Oncoimmunology; 2022; 11(1):2034355. PubMed ID: 35154908
[TBL] [Abstract][Full Text] [Related]
8. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
[TBL] [Abstract][Full Text] [Related]
9. Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1.
Liu F; Zhang H; Shen D; Wang S; Ye Y; Chen H; Pang X; Song Q; He P
J Gastroenterol; 2014 Mar; 49(3):419-26. PubMed ID: 23604623
[TBL] [Abstract][Full Text] [Related]
10. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.
Teijeira A; Migueliz I; Garasa S; Karanikas V; Luri C; Cirella A; Olivera I; Cañamero M; Alvarez M; Ochoa MC; Rouzaut A; Rodriguez-Ruiz ME; Sanmamed MF; Klein C; Umaña P; Ponz M; Bacac M; Melero I
Theranostics; 2022; 12(3):1373-1387. PubMed ID: 35154495
[No Abstract] [Full Text] [Related]
11. Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
Bonnevaux H; Guerif S; Albrecht J; Jouannot E; De Gallier T; Beil C; Lange C; Leuschner WD; Schneider M; Lemoine C; Caron A; Amara C; Barrière C; Siavellis J; Bardet V; Luna E; Agrawal P; Drake DR; Rao E; Wonerow P; Carrez C; Blanc V; Hsu K; Wiederschain D; Fraenkel PG; Virone-Oddos A
Oncoimmunology; 2021; 10(1):1945803. PubMed ID: 34484869
[TBL] [Abstract][Full Text] [Related]
12. An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers.
Wang N; Patel H; Schneider IC; Kai X; Varshney AK; Zhou L
Antib Ther; 2021 Apr; 4(2):90-100. PubMed ID: 34169228
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation.
Kamakura D; Asano R; Kawai H; Yasunaga M
Cancer Immunol Immunother; 2021 Jan; 70(1):177-188. PubMed ID: 32666260
[TBL] [Abstract][Full Text] [Related]
14. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.
Osada T; Hsu D; Hammond S; Hobeika A; Devi G; Clay TM; Lyerly HK; Morse MA
Br J Cancer; 2010 Jan; 102(1):124-33. PubMed ID: 19953093
[TBL] [Abstract][Full Text] [Related]
15. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
16. T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
Quitt O; Luo S; Meyer M; Xie Z; Golsaz-Shirazi F; Loffredo-Verde E; Festag J; Bockmann JH; Zhao L; Stadler D; Chou WM; Tedjokusumo R; Wettengel JM; Ko C; Noeßner E; Bulbuc N; Shokri F; Lüttgau S; Heikenwälder M; Bohne F; Moldenhauer G; Momburg F; Protzer U
J Hepatol; 2021 Nov; 75(5):1058-1071. PubMed ID: 34171437
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer.
Lee HJ; Hong CY; Jin CJ; Kim MH; Lee YK; Nguyen-Pham TN; Lee H; Park BC; Chung IJ; Kim HJ; Lee JJ
Cell Mol Immunol; 2012 Mar; 9(2):175-83. PubMed ID: 22231555
[TBL] [Abstract][Full Text] [Related]
18. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
19. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
20. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
